Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: A meta-analysis

Journal of Clinical Psychopharmacology

Volumn 27, Issue 2, 2007, Pages 198-204

  Paton, Carol ^a   Whittington, Craig ^b   Barnes, Thomas R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; LOXAPINE; NEUROLEPTIC AGENT; PROLACTIN; ZIPRASIDONE;

ABSENCE OF SIDE EFFECTS; AGITATION; ANXIETY; ARTICLE; BODY MASS; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERSALIVATION; MENTAL PATIENT; META ANALYSIS; MOTOR DYSFUNCTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RISK ASSESSMENT; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SIDE EFFECT; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; WEIGHT REDUCTION;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG THERAPY, COMBINATION; GABA ANTAGONISTS; HUMANS; PROLACTIN; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS;

EID: 34247156726     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318036bfbb     Document Type: Article

References (38)

1. Barnes TRE, McEvedy CJB, Nelson HE. Management of treatment-resistant schizophrenia unresponsive to clozapine. Br J Psychiatry. 1996;169(suppl 31):31-40.
2. Buckley P, Miller A, Olsen J, et al. When symptoms persist: clozapine augmentation strategies. Schizophr Bull. 2001;27:615-628.
3. Potter WZ, Ko GN, Zhang LD, et al. Clozapine in China: a review and preview of US/PRC collaboration. Psychopharmacology. 1989;99:S87-S91.
4. Taylor D, Mace S, Mir S, et al. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. Int J Psychiatry Clin Pract. 2000;4:41-46.
5. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, et al. Randomised controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry. 2005;20:409-415.
6. Remington G, Saha A, Chong S-A, et al. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs. 2005;19:843-872.
7. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, et al. Case studies of adjunctive agents in clozapine-resistant schizophrenic patients. Clin Neuropharmacol. 2005;28:50-53.
8. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary 2005. Number 50. London, UK: BMJ Publishing Group and Royal Pharmaceutical Society of Great Britain.
9. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:790-812.
10. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
11. Leucht S, Kane JM, Kissling W, et al. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry. 2005;187:366-371.
12. Higgins JPT, Thompson SG. Quantifying homogeneity in a meta-analysis. Stat Med. 2003;21:1539-1558.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
14. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine; a double-blind, placebo-controlled study. Br J Psychiatry. 1997;171:569-573.
15. Josiassen RC, Ashok J, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2005;162:130-136.
16. Yagcioglu AEA, Akdede BBK, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry. 2005;66:63-72.
17. Honer WG, Thornton AE, Chen EYH, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006;354:472-482.
18. Mowerman S, Siris SG. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. Ann Clin Psychiatry. 1996;8:193-197.
19. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry. 1996;57:395-397.
20. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride adjunction to clozapine in treatment-resistant schizophrenic patients: a preliminary case series study. Eur Psychiatry. 1997;12:152-155.
21. de Groot IW, Heck AH, van Harten PN. Addition of risperidone to clozapine therapy in chronically psychotic inpatients. J Clin Psychiatry. 2001;62:129-130.
22. Munro J, Matthiasson P, Osbourne S, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand. 2004;110:292-298.
23. Ziegenbein M, Kropp S, Kuenzel HE. Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. Clin Neuropharmacol. 2005;28:220-224.
24. Henderson DC, Kunkel L, Nguyen DD, et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand. 2006;113:142-147.
25. Ziegenbein M, Sieberer M, Kuenzel HE, et al. Augmentation of clozapine with amisulpride in patients with treatment-resistant schizophrenia. An open clinical study. German J Psychiatry. 2006;9:17-21.
26. Taylor CG, Flynn SW, Altman S, et al. An open trial of risperidone augmentation of partial response to clozapine. Schizophr Res. 2001;48:156-157.
27. Kaye NS. Ziprasidone augmentation of clozapine in 11 patients. J Clin Psychiatry. 2003;64:215-216.
28. Lerner V, Bergman J, Borokhov A, et al. Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clin Neuropharmacol. 2005;28:66-71.
29. Stern RG, Schmeidler J, Davidson M. Limitations of controlled augmentation trials in schizophrenia. Biol Psychiatry. 1997;42:138-143.
30. Budd S, Brindle N. Clozapine augmentation with sulpiride in schizophrenia. Prog Neurol Psychiatry. 2005;9:9-10.
31. George S, Cowan C. Effectiveness of amisulpride augmentation of clozapine in a non-responder to either drug alone: a case report. Acta Psychiatr Scand. 2005;111:163.
32. Godleski LS, Sernyak MJ. Agranulocytosis after addition of risperidone to clozapine treatment. Am J Psychiatry. 1996;153:735-736.
33. Chong SA, Tan CH, Lee HS. Atrial ectopics with clozapine-risperidone combination. J Clin Psychopharmacol. 1997;17:130-131.
34. Kontaxakis VP, Havaki-Kontaxaki BJ, Stamouli SS, et al. Toxic interaction between risperidone and clozapine: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:407-409.
35. Tyson SC, Devane CL, Risch SC. Pharmacokinetic interaction between risperidone and clozapine. Am J Psychiatry. 1995;152:1401-1402.
36. Vanderzwaag C, McGee M, McEvoy JP, et al. Response of patients with treatment refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry. 1996;153:1579-1583.
37. Perry PJ. Therapeutic drug monitoring of atypical antipsychotics. CNS Drugs. 2000;13:167-171.
38. Greenwood-Smith C, Lubman DI, Castle DJ. Serum clozapine levels: a review of their clinical utility. J Psychopharmacol. 2003;17:234-238.